Jenburkt Pharmaceuticals Limited

BOM:JENBURPHHealthcare

——At close · Market cap —

JENBURPH · Income statement · TradingHolo

INR billions	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	YoY
Revenue	1.1	1.2	1.4	1.4	1.5	1.7	+11.2%
Cost of revenue	0.3	0.3	0.3	0.3	0.3	0.9	+187.7%
Gross profit	0.8	0.9	1.0	1.1	1.2	0.8	−31.6%
Research & development	0.0	0.0	0.0	0.0	0.0	0.0	−100.0%
Selling, general & administrative	0.2	0.3	0.3	0.2	0.2	0.4	+172.7%
Selling & marketing	0.2	0.2	0.1	0.1	0.1	0.0	−100.0%
Operating expenses	0.6	0.3	0.7	0.3	0.5	0.4	−6.0%
Operating income	0.2	0.3	0.3	0.3	0.8	0.4	−46.9%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	+2.0%
Interest income	0.0	0.0	0.0	0.0	0.1	0.0	−100.0%
Other income / expense	0.0	0.0	0.0	0.0	(0.3)	0.1	+118.1%
Pre-tax income	0.2	0.3	0.3	0.4	0.4	0.5	+5.9%
Income tax	0.1	0.1	0.1	0.1	0.1	0.1	−0.8%
Net income	0.2	0.2	0.2	0.3	0.3	0.3	+8.3%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	35.96	48.58	53.90	58.86	72.65	78.71	+8.3%
EPS, diluted (per share)	35.96	48.58	53.90	58.86	72.65	78.71	+8.3%
EBITDA	0.2	0.3	0.4	0.4	0.4	0.5	+24.0%
Depreciation & amortization	0.0	0.0	0.0	0.0	0.0	0.0	+13.9%
Weighted average shares (shares)	4,589,378	4,589,378	4,413,300	4,413,300	4,413,000	4,413,000	+0.0%
Weighted average diluted shares (shares)	4,589,378	4,589,378	4,413,300	4,413,300	4,413,000	4,413,000	+0.0%
Gross margin	72.0%	74.1%	75.2%	77.9%	80.4%	49.4%	−31.0 pts
Operating margin	17.2%	20.5%	21.0%	22.1%	50.4%	24.1%	−26.4 pts
Net margin	15.2%	18.0%	18.1%	18.3%	21.1%	20.6%	−0.5 pts

INR billionsUpdated Tue 31 Mar ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.